Cardiac magnetic resonance analysis shows septal convexity differentiates hypertrophic cardiomyopathy from hypertensive heart disease with high accuracy.
Both hypertrophic cardiomyopathy (HCM) and hypertensive heart disease (HHD) are characterized by left ventricular hypertrophy. Distinguishing HCM from HHD is a common clinical problem, particularly in subjects with moderate left ventricular maximal wall thickness (LVMWT) < 18 mm. Previously, we showed that cardiac magnetic resonance (CMR)-derived septal convexity (SC) into the left ventricle is increased in subjects with HCM-causing mutations with and without LVH. Our objective now was to determine whether CMR-derived SC differentiates HCM from HHD. We measured the maximal distance between the LV septal endocardial border and a line connecting the proximal and distal septal mid-wall points in 4-chamber images, in subjects with hypertension and LVH (n = 29), in subjects with HCM (n = 49), and in healthy controls (n = 20). Here, we show significantly increased SC in subjects with HCM compared to subjects with HHD both in non-indexed and in BSA-indexed measurements. Cutoff SC values of 7.9 mm and 3.7 mm/m2 in all HCM patients and SC values of 7.9 mm and 3.8 mm/m2 in HCM patients with LVMWT < 18 mm differentiated between HCM and HHD with good sensitivity and excellent specificity: SC cutoff value of 7.9 mm had a sensitivity of 77% and a specificity of 90% in all HCM patients, and 67% and 90% in HCM patients with LVMWT < 18 mm, respectively. Our study shows that measuring CMR-derived septal convexity is straightforward and enhances diagnostic performance, providing a novel technique to distinguish between HCM caused by sarcomere mutations and hypertension-induced LVH.
No takes yet. Share an insight, caveat, or question.
Tarkiainen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: